Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac.

In addition to the tumor shrinkage achieved by NDAT–paclitaxel ( Figure 3A ), a clear trend in the reduction in tumor cell viability measured with IVIS reveals a trend in advantage of NDAT–paclitaxel over other drug formulations despite the small tumor size ( Figure 4 ).

also in 19,460 other papers